Executive summary of the European consensus report on the diagnosis and treatment of monoclonal gammopathy of renal significance

Abstract

We introduce the European Union consensus report on the diagnosis and treatment of monoclonal gammopathy of renal significance (MGRS), a generic term to describe kidney disorders caused by a non-malignant monoclonal immunoglobulin clone. There are many subtypes of MGRS, with AL-amyloidosis being most prevalent. The consensus report aims at providing guidance to clinicians, pathologists and laboratory specialists who take care of patients with a (suspected) diagnosis of MGRS. This executive summary provides a condensed overview of the most important aspects of the diagnosis and management of patients with MGRS. Consultation of expert centers is strongly advised. Although most patients will benefit from hematological, clone-directed therapy, treatment decisions must be individualized, in view of the heterogeneity of patients between and within the MGRS subtypes. The final chapter discusses kidney transplantation in patients with MGRS. The working group acknowledges that most advice is based on low-quality evidence. The full report provides the rationale and a detailed discussion of the available literature. This executive summary is an introduction, and not a substitute for the full consensus report.